No profile data available.
Vir Biotechnology, Inc. (VIR) is a healthcare company in the antiviral pharmaceuticals industry, based in San Francisco, United States, with about 408 full-time employees.
It reported revenue of $66.52 million for fiscal year 2025, up 4.4% from fiscal year 2024, and net income of -$437.99 million. Foreign was its largest region in fiscal year 2025, with 97% of revenue. Its market capitalization was $943.27 million as of December 4, 2025.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of December 4, 2025.
, a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally.
Vir Biotechnology reported $66.52 million in revenue for fiscal year 2025, up 4.4% from $63.71 million in fiscal year 2024.
Foreign: 97% of revenue by region in fiscal year 2025, followed by United States (3%).
$943.27 million as of December 4, 2025.
Listed companies of a similar size in the same industry (antiviral pharmaceuticals) include Moderna, Inc. (MRNA), BioNTech SE (BNTX), Novavax, Inc. (NVAX), Valneva SE (VALN).